The aim of this research is to create Controlled Porosity Osmotic Tablets incorporating Tofacitinib Citrate aimed at treating Rheumatoid Arthritis. These tablets operate on the principle of osmosis. Using a 32 factorial design, nine formulations were prepared. The formulation involved a wet granulation method, with the core tablet comprising osmotic agent (NaCl), release retardant (HPMC), and other excipients. A cellulose acetate coating served as the semipermeable membrane, which upon contact with aqueous fluid forms a microporous structure. The evaluation included pre compression parameters, and also post compression parameters. Also SEM analysis was done. Batch F8 exhibited a drug release of 99.80% within 24 hours. Dissolution kinetics were evaluated utilizing multiple pharmacokinetic models including Korsmeyer-Peppas, First order, Higuchi model and zero-order models across all batches.